Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

Last updated: January 26, 2026
Sponsor: City of Hope Medical Center
Overall Status: Active - Not Recruiting

Phase

1

Condition

Ductal Carcinoma In Situ (Dcis)

Breast Cancer

Allergy

Treatment

Quality-of-Life Assessment

Agent Affecting Integumentary System

Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment

Clinical Study ID

NCT05340673
21152
21152
P30CA043703
NCI-2022-01957
  • Ages > 18
  • Female

Study Summary

This clinical trial compares two supplemental topical agents (Aquaphor and Miaderm) for the treatment of acute radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a radiation-induced skin reaction which can cause itching, swelling, pain, and general discomfort. Aquaphor is a commonly available, inexpensive, petrolatum-based multi-purpose ointment designed to protect and sooth extremely dry skin, chapped lips, cracked hands and feet, minor cuts and burns, and many other skin irritations. Miaderm is a water-based cream and contains ingredients like calendula, hyaluronate, and aloe vera which may help reduce occurrence and severity of radiation dermatitis. Both are commonly recommended and used by breast cancer patients undergoing external beam radiation therapy (EBRT). However, it is not known whether one is better than the other in treating or preventing radiation dermatitis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorizedrepresentative.

  • Age > 18 years.

  • Undergoing external beam radiation therapy (EBRT) to the breast or chest wallfollowing surgical resection (lumpectomy or mastectomy) for ductal carcinoma in situ (DCIS) or invasive breast cancer using either conventional fractionation orhypofractionation.

Exclusion

Exclusion Criteria:

  • Partial breast irradiation.

  • Prior radiation overlapping with the intended radiotherapy field.

  • History of systemic radiation sensitivity diseases (xeroderma pigmentosum, ataxiatelangiectasia).

  • Extreme hypofractionation (less than 15 fractions of radiation).

  • Palliative treatment.

  • Patient intention to use topical product other than Aquaphor or Miaderm.

  • Inflammatory breast cancer, skin involvement, planned use of bolus.

Study Design

Total Participants: 208
Treatment Group(s): 4
Primary Treatment: Quality-of-Life Assessment
Phase: 1
Study Start date:
June 21, 2022
Estimated Completion Date:
December 15, 2026

Study Description

PRIMARY OBJECTIVE:

I. Determine the efficacy of Miaderm compared to Aquaphor in the treatment and/or prevention of radiation dermatitis caused by EBRT in breast cancer patients undergoing EBRT to the breast/chest wall.

SECONDARY OBJECTIVE:

I. Determine quality of life (QoL) and need for additional concomitant therapies to address dermatitis in breast cancer patients undergoing EBRT to the breast/chest wall using Miaderm compared to Aquaphor.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Beginning on day 1 of radiation therapy, patients apply Aquaphor twice daily (BID), but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.

ARM II: Beginning on day 1 of radiation therapy, patients apply Miaderm BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.

After completion of study treatment, patients are followed up at 2 weeks and then at 90-120 days.

Connect with a study center

  • City of Hope Medical Center

    Duarte, California 91010
    United States

    Site Not Available

  • City of Hope Medical Center

    Duarte 5344147, California 5332921 91010
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.